一种小分子对人类铜转运的抑制作用可显著减弱癌细胞的增殖。
Inhibition of human copper trafficking by a small molecule significantly attenuates cancer cell proliferation.
作者信息
Wang Jing, Luo Cheng, Shan Changliang, You Qiancheng, Lu Junyan, Elf Shannon, Zhou Yu, Wen Yi, Vinkenborg Jan L, Fan Jun, Kang Heebum, Lin Ruiting, Han Dali, Xie Yuxin, Karpus Jason, Chen Shijie, Ouyang Shisheng, Luan Chihao, Zhang Naixia, Ding Hong, Merkx Maarten, Liu Hong, Chen Jing, Jiang Hualiang, He Chuan
机构信息
Department of Chemistry, Department of Biochemistry and Molecule Biology, Institute for Biophysical Dynamics, The University of Chicago, 929 East 57th Street, Chicago, Illinois 60637, USA.
Howard Hughes Medical Institute, The University of Chicago, 929 East 57th Street, Chicago, Illinois 60637, USA.
出版信息
Nat Chem. 2015 Dec;7(12):968-79. doi: 10.1038/nchem.2381. Epub 2015 Nov 9.
Copper is a transition metal that plays critical roles in many life processes. Controlling the cellular concentration and trafficking of copper offers a route to disrupt these processes. Here we report small molecules that inhibit the human copper-trafficking proteins Atox1 and CCS, and so provide a selective approach to disrupt cellular copper transport. The knockdown of Atox1 and CCS or their inhibition leads to a significantly reduced proliferation of cancer cells, but not of normal cells, as well as to attenuated tumour growth in mouse models. We show that blocking copper trafficking induces cellular oxidative stress and reduces levels of cellular ATP. The reduced level of ATP results in activation of the AMP-activated protein kinase that leads to reduced lipogenesis. Both effects contribute to the inhibition of cancer cell proliferation. Our results establish copper chaperones as new targets for future developments in anticancer therapies.
铜是一种过渡金属,在许多生命过程中发挥着关键作用。控制细胞内铜的浓度和运输为破坏这些过程提供了一条途径。在此,我们报告了能够抑制人类铜转运蛋白Atox1和CCS的小分子,从而提供了一种破坏细胞铜运输的选择性方法。敲低Atox1和CCS或抑制它们会导致癌细胞的增殖显著降低,但正常细胞不受影响,同时在小鼠模型中肿瘤生长也会减缓。我们表明,阻断铜运输会诱导细胞氧化应激并降低细胞ATP水平。ATP水平的降低导致AMP激活的蛋白激酶活化,进而导致脂肪生成减少。这两种效应都有助于抑制癌细胞增殖。我们的结果确立了铜伴侣蛋白作为未来抗癌治疗新靶点的地位。